CaMKII Inhibitor Disappoints in Post-MI Cardioprotection

(MedPage Today) -- The first calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor to be tested for prevention of post-MI heart failure stumbled in a small phase II trial.
Among patients who had residual left ventricular (LV) dysfunction...